Investigational drug · Phase 2
INX-315
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "INX-315"
First trial start
2023
Mar 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INX-315", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Breast Cancer Metastatic
- Hormone Receptor Positive Tumor
- Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
- Ovarian Cancer
- CCNE1 Amplification
- Solid Tumor
- Advanced Cancer
- Metastatic Cancer
Approved drugs for the same conditions: Breast cancer · Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "INX-315" as an intervention, largest first.
Incyclix BioIndustry
NCT05735080 · 150 participants (planned) · Start Mar 28, 2023 · Primary completion Jul 2027
Drug: INX-315; Fulvestrant and 1 more · For: Breast Cancer; Breast Cancer Metastatic; Hormone Receptor Positive Tumor and 6 more
Sites: Orlando, Florida; Atlanta, Georgia; Augusta, Georgia · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Correction: INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors.
Dietrich C, Trub A, Ahn A, et al. · Cancer Discov 2025
- Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle.
Kumarasamy V, Wang J, Roti M, et al. · Nat Commun 2025
- A Highly Anticipated Selective Therapeutic Agent against CDK2: INX-315.
Watts LP, Spencer SL · Cancer Discov 2024
- INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors.
Dietrich C, Trub A, Ahn A, et al. · Cancer Discov 2024
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.